96 well flashplate basic microplates (Revvity)
Revvity is a verified supplier 
Revvity manufactures this product 
90
Structured Review
Revvity
96 well flashplate basic microplates
96 Well Flashplate Basic Microplates, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microplate+basic+flashplates/FlashPlate+Basic+Microplate%2C+50+Plates/pm17383582-42-2-6
Average 90 stars, based on 4 article reviews
96 Well Flashplate Basic Microplates, supplied by Revvity, used in various techniques. Bioz Stars score: 90/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microplate+basic+flashplates/FlashPlate+Basic+Microplate%2C+50+Plates/pm17383582-42-2-6
Average 90 stars, based on 4 article reviews
96 well flashplate basic microplates - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Effective specific activities determined by scintillation proximity counting for production runs of [(18)F]FES and 4F-M[(18)F]FES. Article Snippet: Introduction: 16a-[F]Fluoro-17h-estradiol ([F]FES) and various derivatives can be used to image noninvasively the expression of estrogen receptors in breast cancer.. A high specific activity is required for successful visualization of ER expression in vivo, particularly for small animal imaging.. We describe a simple method for effective specific activity (ESA) measurements of ER-binding ligands. Sterility:Article Title: Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Article Snippet: Transforming growth factor 1 (TGF1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix.. TGF1 acts through the TGFtype I and type II receptors to activate intracellular mediators, such as Smad proteins, the p38 mitogen-activated protein kinase (MAPK), and the extracellular signal-regulated kinase pathway.. We expressed the kinase domain of the TGFtype I receptor [activin receptor-like kinase (ALK)5] and the substrate, Smad3, and determined that SB431542 is a selective inhibitor of Smad3 phosphorylation with an IC50 of 94 nM. Incubation:Article Title: Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors through Docking-Based Virtual Screening Article Snippet: The DNA methyltransferases (DNMTs) found in mammals include DNMT1, DNMT3A and DNMT3B, and are attractive targets in cancer chemotherapy.. DNMT1 was the first among the DNMTs to be characterized, and it is responsible for maintaining DNA methylation patterns.. A number of DNMT inhibitors have been reported, but most of them are nucleoside analogs that can lead to toxic side-effects and lack specificity. Article Title: Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors Article Snippet: Accepted Manuscript Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors Zigao Yuan, Qinsheng Sun, Dan Li, Shuangshuang Miao, Shaopeng Chen, Lu Song, Chunmei Gao, Yuzong Chen, Chunyan Tan, Yuyang Jiang PII: S0223-5234(17)30272-6 DOI: 10.1016/j.ejmech.2017.04.017 Reference: EJMECH 9364 To appear in: European Journal of Medicinal Chemistry Received Date: 8 February 2017 Revised Date: 1 April 2017 Accepted Date: 8 April 2017 Please cite this article as: Z. Yuan, Q.. Sun, D. Li, S. Miao, S. Chen, L. Song, C. Gao, Y. Chen, C. Tan, Y. Jiang, Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors, European Journal of Medicinal Chemistry (2017), doi: 10.1016/ j.ejmech.2017.04.017.. This is a PDF file of an unedited manuscript that has been accepted for publication. |